Compugen Ltd. · NASDAQ:CGEN
Compugen — Investor Presentation (February 2022)
33 slides from Compugen's investor presentation, February 2022
Slide 1: Corporate Overview
Corporate Over view February 2022
Slide 2: Safe Harbor Statement
S a fe H a r b o r S tate m e nt This presentation contains “forward-looking statements” within the meaning of the delays in the conduct of its clinical trials as well as significant increased expenditures; Securities Act of 1933 and the Securities Exchange Act of 1934, as amended, and the Compugen’
Slide 3: Our Vision
Our Vision Transforming patient lives by developing first-in-class therapeutics based on Compugen’s computational target discovery platform From Code to Cure® 3
Slide 4: Investment highlights
I nve st m e nt h i g h l i g ht s EXPAND MAXIMIZE ADVANCE number of patients responding value for patients immuno-oncology research to treatment • Lead assets in Phase 1 • Strategic collaborations with Pharma • Predictive computational platform of • COM701 (anti-PVRIG) and academic institutions inc
Slide 5: Compugen's immuno-oncology pipeline
C o m p u ge n ’s i m m u n o - o n c o l o g y p i p e l i n e Executing a unique combination approach PROGRAM TARGET PARTNER INDICATION STAGE OF DEVELOPMENT COM701 PVRIG Ovarian, Breast, Endometrial, CRC (MSS) and NSCLC Phase 1 COM701 + nivolumab PVRIG, PD-1 Bristol Myers Squibb Ovarian, Breast, E
Slide 6: Partnerships with leading pharma companies
Pa r t n e rs h i p s w i t h l e a d i n g p h a r m a c o m p a n i e s Clinical Trial Collaboration and Equity Development and License Agreement License Agreement Investment October 2018 August 2013 March 2018 Collaborate on COM701 combo studies Development of an antibody based on a target Develo
Slide 7: Well executed and milestone rich
We l l exe c u te d m i l e sto n e r i c h 2 0 2 1 Striding forward as the leaders in the DNAM -1 axis, executing a unique combination approach Completed Completed all dose escalation studies clinical studies Presented COM701 mono and dual combination data with nivolumab EXPAND Presented First to p
Slide 8: Expected 2022/2023+ catalysts
E x p e c te d 2 0 2 2 / 2 0 2 3 c ata l yst s Reported data will guide regulatory strategy defined on a cohort -by-cohort basis H2 2022 2023+ Anti-tumor activity, translational and Anti-tumor activity, translational and safety data from anticipated fully enrolled cohorts: safety data from: • COM701
Slide 9: Pioneering predictive computational discovery platform
P i o n e e r i n g p re d i c t i ve c o m p u tat i o n a l d i s c o ve r y p l at fo r m From target discovery to clinical validation Discover Novel Targets TIGIT PVRIG RNASeq Spatial Omics Proprietary computational tools and algorithms ILDR2 Undisclosed First-in-Class Curation Annotation Integr
Slide 10: Diverse experienced leadership team
D i ve rs e ex p e r i e n c e d l e a d e rs h i p te a m Management team Board Of Directors Paul Sekhri Chairman of the Board Anat Cohen-Dayag, PhD Ari Krashin Henry Adewoye, MD Anat Cohen-Dayag, PhD President & CEO Chief Financial & Operating Officer SVP, Chief Medical Officer President & CEO, Di
Slide 11: Strategic advisors
S t rate g i c a d v i s o rs Industry veterans, renowned oncologists and immunologists Scientific Advisory Board Drew Pardoll, MD, PhD Antoni Ribas, MD, PhD Nils Lonberg, PhD Elliott Sigal, MD, PhD Chairman Former SVP, Oncology Discovery Biology Strategic Advisor Multi-year strategic collaboration
Slide 12: DNAM axis potential to be a game changer in the fight against cancer
D N A M ax i s p o te nt i a l to b e a ga m e c h a n ge r i n t h e f i g ht a ga i n st c a n c e r PVRIG may be the missing piece when current checkpoint inhibitors fail • PVRIG and TIGIT discovered by Compugen’s discovery platform • DNAM axis – two parallel and complementary inhibitory pathways
Slide 13: PVRIG and TIGIT – Complementary but distinct pathways
P V R I G A N D T I G I T – C o m p l e m e nta r y b u t d i st i n c t p at hway s PVRIG preferentially binds PVRL2 TIGIT preferentially binds PVR Differentially expressed in Differentially expressed on Differentially expressed in the tumor types immune cell types tumor microenvironment PVRL2 expr
Slide 14: Biomarker driven approach
B i o m a r ke r d r i ve n a p p ro a c h Ta r g e t i n g t u m o r t y p e s m o s t l i ke l y t o r e s p o n d t o t r e a t m e n t Indication selection for cohort ID of biomarkers for future PD biomarkers expansion studies patient selection to validate MOA Driven by computational discovery E
Slide 15: COM701, COM902 data reported
CO M 7 0 1 , CO M 9 0 2 d ata re p o r te d All comer patients progressed on standard of care COM701 COM701 dose COM701 Open label + nivolumab + COM902 escalation & + nivolumab design BMS-986207 dose escalation expansion dose escalation dose escalation Phase 1 1 1 1 # of patients 36 15 13 18 COM701
Slide 16: COM701, COM902 ongoing clinical cohort expansion program
CO M 7 0 1 , CO M 9 0 2 o n go i n g c l i n i c a l c o h o r t ex p a n s i o n p ro g ra m Patients who have progressed on standard of care COM701 + COM701 + Open label COM701 + COM902 nivolumab + anti- COM902 both design nivolumab RDFE TIGIT BMS-986207 at RDFE Phase 1 1/2 1 1 # of patients 20 pe
Slide 17: Swimmer plot COM701 monotherapy dose escalation and expansion
Sw i m m e r p l o t CO M 7 0 1 m o n o t h e ra p y d o s e e s c a l at i o n a n d ex p a n s i o n I nve st i gato r a s s e s s e d re s p o n s e s Activity also seen in PD -L1 low tumors 180 days A: 20 mg/kg IV Q4W Primperitoneal 557 A: 0.3 mg/kg IV Q3W 379 Adenoid cycstic A: 10 mg/kg IV Q3W
Slide 18: Swimmer plot COM701 with nivolumab
Sw i m m e r p l o t CO M 7 0 1 w i t h n i vo l u m a b I nve st i gato r a s s e s s e d re s p o n s e s Activity also seen in PD -L1 low tumors COM701 + nivolumab dose escalation 180 days 0.3 mg/kg IV Q3W/360 mg Anal SCC 676 10 mg/kg IV Q4W/480 mg RCC 526 1 mg/kg IV Q3W/360 mg Endometrial 321 0.
Slide 19: COM701, nivolumab and BMS-986207 combination well tolerated
CO M 7 0 1 , n i vo l u m a b a n d B M S - 9 8 6 2 0 7 c o m b i n at i o n we l l to l e rate d i n d o s e e s c a l at i o n st u d y 20 mg/kg Prostate cancer 113 Favorable safety and 10 mg/kg Gastric cancer 111 0.3 mg/kg Ovarian cancer 75*† tolerability 3 mg/kg NSCLC 63 1 mg/kg CRC 58* COM701 D
Slide 20: Potent activation of the immune system with triple blockade
Po te nt a c t i vat i o n o f t h e i m m u n e sy ste m w i t h CO M 7 0 1 , n i vo l u m a b a n d B M S - 9 8 6 2 0 7 t r i p l e b l o c ka d e Increased T and NK cell activation, memory T Cell proliferation and IFNg induction in blood at all COM701 doses A 24 Avr. Fold Change=2.7 P=<0.0001 ***
Slide 21: COM902 monotherapy well tolerated in dose escalation study
CO M 9 0 2 m o n o t h e ra p y we l l to l e rate d i n d o s e e s c a l at i o n st u d y 1 mg/kg Chordoma 344† Favorable safety and 0.01 mg/kg Adenoid-cystic CA trachea 302† 0.01 mg/kg 291 tolerability 1 mg/kg Rectal CA Ovarian CA 131 0.1 mg/kg Peritoneal CA 83† 1 mg/kg Appendiceal CA 83* 10 mg/
Slide 22: COM902 avoids depletion of major TIGIT+ expressing lymphocytes
CO M 9 0 2 avo i d s d e p l et i o n o f m a j o r T I G I T + ex p re s s i n g l y m p h o c y te s - N K , C D 4 a n d C D 8 T c e l l s Supporting rationale for selecting high affinity COM902 as a IgG4 reduced Fc effector function anti-TIGIT antibody CD4+ Naive CD8+ Naive CD4+ CM CD8+ CM 100 CD
Slide 23: Appendix
APPENDIX
Slide 24: An opportunity to address a significant unmet need
A n o p p o r t u n i t y to a d d re s s a s i g n i f i c a nt u n m et n e e d 70-80% of patients non -responsive to approved cancer immunotherapies PD-1 monotherapy/combination activity across indications 100 90 • Clinical strategy primarily focused on PD-1 non- Overall response Rate % 80 ~20-30
Slide 25: COM701: A potentially first-in-class anti-PVRIG antibody
CO M 7 0 1 : A p o te nt i a l l y f i rst - i n - c l a s s a nt i - P V R I G a nt i b o d y Dose escalation studies clear the path for ongoing cohort Combination therapy strategy based on deep expansion studies in select tumor types understanding of DNAM1 axis biology • Well-tolerated in mono, du
Slide 26: Summary of investigator-assessed response
S u m m a r y o f i nve st i gato r - a s s e s s e d re s p o n s e CO M 7 0 1 m o n o t h e ra p y a n d d u a l c o m b i n at i o n w i t h n i vo l u m a b ( P e r R E C I S T v 1 . 1 D LT - E v a l u a b l e P o p u l a t i o n ) Data from monotherapy and combination dose escalation and monoth
Slide 27: Spider and waterfall plots - COM701 mono and dual combo with nivolumab
S p i d e r a n d wate r fa l l p l o t s - CO M 7 0 1 m o n o a n d d u a l c o m b o w i t h n i vo l u m a b 10 patients with SD, PR, CR ≥ 6 months Monotherapy and Combination Dose Escalation DLT-Evaluable Population and Monotherapy Expansion Arm with Evaluable and Measurable Target Lesions: Mono
Slide 28: Confirmed PR ongoing treatment in patient with primary peritoneal cancer
C o n f i r m e d P R o n go i n g t re at m e nt 1 8 m o nt h s i n p at i e nt w i t h p r i m a r y p e r i to n e a l c a n c e r ( p l at i n u m re s i sta nt , M S S ) 63-year-old female with microsatellite stable platinum resistant primary peritoneal cancer Had 3 prior lines of SOC treatment
Slide 29: Confirmed CR ongoing treatment in patient with anal SCC
C o n f i r m e d C R o n go i n g t re at m e nt fo r 2 2 m o nt h s i n p at i e nt with anal SCC HPV+ 57-year-old female patient with evaluable disease but not measurable per RECIST v1.1 at study entry (not mandatory in dose escalation) Had 3 prior lines of chemotherapy • 5-FU/mitomycin, SD (best
Slide 30: COM701 alone and with nivolumab associated with immune activation in peripheral blood
CO M 7 0 1 a l o n e a n d w i t h n i vo l u m a b a s s o c i ate d w i t h i m m u n e a c t i vat i o n i n p e r i p h e ra l b l o o d Trend of increasing proliferation of CD8+ TEM Increase in serum IFNγ with a trend for (effector memory T cells) and NK-T cells COM701 dose dependency COM701 Mo
Slide 31: Induction of activated DC markers in serum of patients responding to COM701 + nivolumab
I n d u c t i o n o f a c t i vate d D C m a r ke rs i n s e r u m o f p at i e nt s re s p o n d i n g to CO M 7 0 1 + n i vo l u m a b 2 patients who responded to treatment with COM701 + nivolumab had a higher induction of activated DC markers in their serum compared to non-responders LAMP3 HLA-DR
Slide 32: PVRIG uniquely clusters with early memory differentiation/stem-like genes
P V R I G u n i q u e l y c l u ste rs w i t h e a r l y m e m o r y d i f fe re nt i at i o n / ste m - l i ke ge n e s P o t e n t i a l f o r o p t i m a l Ts c m a c t i v a t i o n , e x p a n s i o n a n d g e n e r a t i o n o f e f f e c t o r T c e l l s PCA Analysis of CD8+ T cell genes, N
Slide 33: PVRIG/PVRL expression on key immune cell populations
P V R I G / P V R L 2 ex p re s s i o n o n key i m m u n e c e l l p o p u l at i o n s I n v o l v e d i n T c e l l p r i m i n g ( T SCM, T L S a n d D C ) PVRIG expression on TSCM cells PVRL2 expression across various dendritic cell types PVRIG TIGIT PD-1 RNA Expression NSCLC sample; PVRL2 sing